High variability in baseline urinary free cortisol values in patients with Cushing's disease
S Petersenn, J Newell-Price, J W Findling, F Gu, M Maldonado, K Sen, L R Salgado, A Colao, B M K Biller, Pasireotide B2305 Study Group, R Abs, B Allolio, R Auchus, J Bertherat, B M K Biller, C Boguszewski, M Boscaro, T Brue, O Bruno, P Caron, D Carvalho, F Cavagnini, O Chabre, A Chervin, C Chik, A Colao, A Çömlekçi, C Cortet, M Czepielewski, E Degli Uberti, A Estour, U Feldt-Rasmussen, M Fleseriu, P Freda, M Gadelha, M Gershinsky, E Ghigo, B Glaser, F Gu, M Guitelman, S Guler, A Hamrahian, S A Imran, Z Jin, J O Jorgensen, P Kadĭoğlu, L Katznelson, A Lacroix, A Leal Cerro, P Loli, L Lu, W Ludlam, F Mantero, E Martino, M Mercado, A Moreira, G Ning, K Nogueira, L Østergaard Kristensen, S Petersenn, G Piaditis, L Portocarrero, V Rohmer, R Rubens, L Salgado, S Samson, J Schopohl, I Shimon, C Strasburger, A Tabarin, M Terzolo, S Tsagarakis, N Unger, Z Valkusz, M Välimäki, L Van Gaal, E Vidal, S Webb, R Weiss, W Zglicyński, S Petersenn, J Newell-Price, J W Findling, F Gu, M Maldonado, K Sen, L R Salgado, A Colao, B M K Biller, Pasireotide B2305 Study Group, R Abs, B Allolio, R Auchus, J Bertherat, B M K Biller, C Boguszewski, M Boscaro, T Brue, O Bruno, P Caron, D Carvalho, F Cavagnini, O Chabre, A Chervin, C Chik, A Colao, A Çömlekçi, C Cortet, M Czepielewski, E Degli Uberti, A Estour, U Feldt-Rasmussen, M Fleseriu, P Freda, M Gadelha, M Gershinsky, E Ghigo, B Glaser, F Gu, M Guitelman, S Guler, A Hamrahian, S A Imran, Z Jin, J O Jorgensen, P Kadĭoğlu, L Katznelson, A Lacroix, A Leal Cerro, P Loli, L Lu, W Ludlam, F Mantero, E Martino, M Mercado, A Moreira, G Ning, K Nogueira, L Østergaard Kristensen, S Petersenn, G Piaditis, L Portocarrero, V Rohmer, R Rubens, L Salgado, S Samson, J Schopohl, I Shimon, C Strasburger, A Tabarin, M Terzolo, S Tsagarakis, N Unger, Z Valkusz, M Välimäki, L Van Gaal, E Vidal, S Webb, R Weiss, W Zglicyński
Abstract
Objective: Twenty-four-hour urinary free cortisol (UFC) sampling is commonly used to evaluate Cushing's syndrome. Because there are few data on UFC variability in patients with active Cushing's disease, we analysed baseline UFC in a large patient cohort with moderate-to-severe Cushing's disease and assessed whether variability correlates with hypercortisolism severity. These data will help clinicians establish the minimum number of UFC samples required to obtain reliable data.
Design: Observational study (enrolment phase of Phase III study).
Methods: Patients (n = 152) with persistent/recurrent or de novo Cushing's disease and mean UFC (mUFC) ≥1·5×ULN (normal: 30-145 nmol/24 h) were included. Mean UFC level was calculated from four 24-h urine samples collected over 2 weeks.
Results: Over 600 24-h UFC samples were analysed. The mUFC levels of samples 1 and 2 and samples 3 and 4 were 1000 nmol/24 h (SD 1872) and 940 nmol/24 h (SD 2148), respectively; intrapatient coefficient of variation (CV) was 38% for mUFC. The intrapatient CV using all four samples was 52% (95% CI: 48-56). The intrapatient CV was 51% (95% CI: 44-58) for samples 1 and 2, 49% (95% CI: 43-56) for samples 3 and 4 and 54% (95% CI: 49-59) for samples 1, 2 and 3. Variability in mUFC increased as UFC levels increased. There were no correlations between UFC and clinical features of hypercortisolism.
Conclusions: There is intrapatient variability of approximately 50% in 24-h UFC measurements, which is relevant to targets set to estimate any treatment effect. Analysing more than two 24-h collection periods in individual patients does not result in a relevant decrease in variability. Interestingly, UFC levels did not correlate with hypercortisolism severity.
Trial registration: ClinicalTrials.gov NCT00434148.
© 2013 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
Figures
References
- Bertagna X, Guignat L, Groussin L, et al. Cushing’s disease. Best Practice and Research Clinical Endocrinology and Metabolism. 2009;23:607–623.
- Newell-Price J, Bertagna X, Grossman AB, et al. Cushing’s syndrome. The Lancet. 2006;367:1605–1617.
- Clayton RN, Raskauskiene D, Reulen RC, et al. Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. Journal of Clinical Endocrinology and Metabolism. 2011;96:632–642.
- Webb SM, Badia X, Barahona MJ, et al. Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. European Journal of Endocrinology. 2008;158:623–630.
- Etxabe J. Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clinical Endocrinology. 1994;40:479–484.
- Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. Journal of Clinical Endocrinology and Metabolism. 2007;92:976–981.
- Swearingen B, Biller BM, Barker FG, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Annals of Internal Medicine. 1999;130:821–824.
- Boscaro M. Arnaldi G. Approach to the patient with possible Cushing’s syndrome. Journal of Clinical Endocrinology and Metabolism. 2009;94:3121–3131.
- Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2008;93:1526–1540.
- Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. Journal of Clinical Endocrinology and Metabolism. 2008;93:1553–1562.
- Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. Journal of Clinical Endocrinology and Metabolism. 2009;94:223–230.
- Godbout A, Manavela MP, Danilowicz K, et al. Cabergoline monotherapy in the long-term treatment of Cushing’s disease. European Journal of Endocrinology. 2010;163:709–716.
- Colao A, Petersenn S, Newell-Price J, et al. A 12-month Phase 3 study of pasireotide in Cushing’s disease. The New England Journal of Medicine. 2012;366:914–924.
- Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome. The New England Journal of Medicine. 1991;325:897–905.
- Malerbi DA, Mendonca BB, Liberman B, et al. The desmopressin stimulation test in the differential diagnosis of Cushing’s syndrome. Clinical Endocrinology. 1993;38:463–472.
- Turpeinen U, Markkanen H, Valimaki M, et al. Determination of urinary free cortisol by HPLC. Clinical Chemistry. 1997;43:1386–1391.
- Quan H. Shih WJ. Assessing reproducibility by the within-subject coefficient of variation with random effects models. Biometrics. 1996;52:1195–1203.
- Besemer F, Pereira AM. Smit JW. Alcohol-induced Cushing syndrome. Hypercortisolism caused by alcohol abuse. The Netherlands Journal of Medicine. 2011;69:318–323.
- Invitti C, Pecori Giraldi F, Dubini A, et al. Increased urinary free cortisol and decreased serum corticosteroid-binding globulin in polycystic ovary syndrome. Acta Endocrinologica (Copenhagen) 1991;125:28–32.
- Vierhapper H, Kiss A, Nowotny P, et al. Metabolism of cortisol in anorexia nervosa. Acta Endocrinologica (Copenhagen) 1990;122:753–758.
- Viardot A, Huber P, Puder JJ, et al. Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. Journal of Clinical Endocrinology and Metabolism. 2005;90:5730–5736.
- Starkman MN, Giordani B, Berent S, et al. Elevated cortisol levels in Cushing’s disease are associated with cognitive decrements. Psychosomatic Medicine. 2001;63:985–993.
- Sonino N, Fava GA, Raffi AR, et al. Clinical correlates of major depression in Cushing’s disease. Psychopathology. 1998;31:302–306.
- Bakker RC, Gallas PR, Romijn JA, et al. Cushing’s syndrome complicated by multiple opportunistic infections. Journal of Endocrinological Investigation. 1998;21:329–333.
- Graham BS. Tucker WS., Jr Opportunistic infections in endogenous Cushing’s syndrome. Annals of Internal Medicine. 1984;101:334–338.
- Del Dotto P. Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clinical Pharmacokinetics. 2003;42:633–645.
- Pecori Giraldi F, Moro M. Cavagnini F. Gender-related differences in the presentation and course of Cushing’s disease. Journal of Clinical Endocrinology and Metabolism. 2003;88:1554–1558.
- Findling JW, Pinkstaff SM, Shaker JL, et al. Pseudohypercortisoluria: spurious elevation of urinary cortisol due to carbamazepine. The Endocrinologist. 1998;8:51–54.
- Meikle AW, Findling J, Kushnir MM, et al. Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography. Journal of Clinical Endocrinology and Metabolism. 2003;88:3521–3524.
Source: PubMed